

- Fialkow PJ, Janssen J, Bartram CR. Clonal remissions in acute nonlymphocytic leukemia: evidence for a multistep pathogenesis of the malignancy. *Blood* 1991;77:1415–1417.
- Reya T, Morrison SJ, Clarke MF, et al. Stem cells, cancer, and cancer stem cells. *Nature* 2001;414:105–111.
- Jones RJ, Matsui W. Cancer stem cells: from bench to bedside. *Biol Blood Marrow Transplant* 2007;13:47–52.
- Holowiecki J, Grosicki S, Giebel S, et al. Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study. *J Clin Oncol* 2012;30:2441–2448.
- Lowenberg B, Pabst T, Vellenga E, et al. Cytarabine dose for acute myeloid leukemia. *N Engl J Med* 2011;364:1027–1036.
- Pui CH, Ribeiro RC, Hancock ML, et al. Acute myeloid leukemia in children treated with epidophyllotoxins for acute lymphoblastic leukemia. *N Engl J Med* 1991;325:1682–1687.
- Armitage JO, Carbone PP, Connors JM, et al. Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients. *J Clin Oncol* 2003;21:897–906.
- Andersen MK, Christiansen DH, Jensen BA, et al. Therapy-related acute lymphoblastic leukaemia with MLL rearrangements following DNA topoisomerase II inhibitors, an increasing problem: report on two new cases and review of the literature since 1992. *Br J Haematol* 2001;114:539–543.
- Stoffel TJ, Nesbit ME, Levitt SH. Extramedullary involvement of the testes in childhood leukemia. *Cancer* 1975;35:1203–1211.
- Cheson BD, Cassileth PA, Head DR, et al. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. *J Clin Oncol* 1990;8:813–819.
- Bennett J, Catovsky D, Daniel MT, et al. The morphological classification of acute lymphoblastic leukaemia: concordance among observers and clinical correlations. *Br J Haematol* 1981;47:553–561.
- Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. *J Clin Oncol* 1999;17:3835–3849.
- Mastrangelo R, Poplack D, Bleyer A, et al. Report and recommendations of the rome workshop concerning poor-prognosis acute lymphoblastic leukemia in children: biologic bases for staging, stratification, and treatment. *Med Pediatr Oncol* 1986;14:191–194.
- Mahmoud HH, Rivera GK, Hancock ML, et al. Low leukocyte counts with blast cells in cerebrospinal fluid of children with newly diagnosed acute lymphoblastic leukemia. *N Engl J Med* 1993;329:314–319.
- Bürger B, Zimmermann M, Mann G, et al. Diagnostic cerebrospinal fluid examination in children with acute lymphoblastic leukemia: significance of low leukocyte counts with blasts or traumatic lumbar puncture. *J Clin Oncol* 2003;21:184–188.
- Walter RB, Othus M, Borthakur G, et al. Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment. *J Clin Oncol* 2011;29:4417–4423.
- Othus M, Kantarjian H, Petersdorf S, et al. Declining rates of treatment-related mortality in patients with newly diagnosed AML given 'intense' induction regimens: a report from SWOG and MD Anderson. *Leukemia* 2014;28:289–292.
- Downing JR. The core-binding factor leukemias: lessons learned from murine models. *Curr Opin Genet Dev* 2003;13:48–54.
- Appelbaum FR, Kopecky KJ, Tallman MS, et al. The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations. *Br J Haematol* 2006;135:165–173.
- Buccisano F, Maurillo L, Spagnoli A, et al. Cytogenetic and molecular diagnostic characterization combined to postconsolidation minimal residual disease assessment by flow cytometry improves risk stratification in adult acute myeloid leukemia. *Blood* 2010;116:2295–2303.
- Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. *J Clin Oncol* 2003;21:4642–4649.
- Dohner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. *Blood* 2010;115:453–474.
- de Lima M, Strom SS, Keating M, et al. Implications of potential cure in acute myelogenous leukemia: development of subsequent cancer and return to work. *Blood* 1997;90:4719–4724.
- Walter RB, Kantarjian HM, Huang X, et al. Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: a combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study. *J Clin Oncol* 2010;28:1766–1771.
- Chen X, Xie H, Bohm C, et al. The relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia. *ASH Annual Meeting Abstracts* 2012;120:1418.
- Büchner T, Hiddemann W, Berdel WE, et al. 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group. *J Clin Oncol* 2003;21:4496–4504.
- Appelbaum FR, Gundacker H, Head DR, et al. Age and acute myeloid leukemia. *Blood* 2006;107:3481–3485.
- Yanada M, Garcia-Manero G, Borthakur C, et al. Relapse and death during first remission in acute myeloid leukemia. *Haematologica* 2008;93:633–634.
- Sudipto M, Sekeres MA, Godwin J, et al. Prediction of CR on reinduction in patients with newly diagnosed acute myeloid leukemia given intensive induction regimens: a report from SWOG and Cleveland Clinic. *Blood* 2013;122:3924.
- Appelbaum FR, Petersdorf S, Erba HP, et al. Evaluation of which patients get a second course of 3+7 on cooperative group trials for newly diagnosed acute myeloid leukemia: a report from SWOG. *Blood* 2013;122:3925.
- Fernandez HF, Sun Z, Yao X, et al. Anthracycline dose intensification in acute myeloid leukemia. *N Engl J Med* 2009;361:1249–1259.
- Löwenberg B, Ossenkoppele GJ, van Putten W, et al. High-dose daunorubicin in older patients with acute myeloid leukemia. *N Engl J Med* 2009;361:1235–1248.
- Bertoli S, Delabesse E, Mozziconacci MJ, et al. Impact of anthracycline dose intensification on minimal residual disease and outcome of core binding factors acute myeloid leukemias. *Blood* 2013;122:2681.
- Gardin C, Chevret S, Pautas C, et al. Superior long-term outcome with idarubicin compared with high-dose daunorubicin in patients with acute myeloid leukemia age 50 years and older. *J Clin Oncol* 2013;31:321–327.
- Löwenberg B. Sense and nonsense of high-dose cytarabine for acute myeloid leukemia. *Blood* 2013;121:26–28.
- Dillman R, Davis R, Green M, et al. A comparative study of two different doses of cytarabine for acute myeloid leukemia: a phase III trial of Cancer and Leukemia Group B. *Blood* 1991;78:2520–2526.
- Othus M, Faderl SH, Stirewalt DL, et al. Impact of cytarabine dose in the induction regimen on the outcome of patients with newly diagnosed acute myeloid leukemia with or without NPM1 and/or FLT3 mutations: a SWOG and MD Anderson Cancer Center Report. *Blood* 2013;122:2686.
- Bloomfield CD, Lawrence D, Byrd JC, et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. *Cancer Res* 1998;58:4173–4179.
- Burnett AK, Russell NH, Hills RK, et al. Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial. *J Clin Oncol* 2013;31:3360–3368.
- Yin JA, O'Brien MA, Hills RK, et al. Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial. *Blood* 2012;120:2826–2835.
- Schnittger S, Kern W, Tschulik C, et al. Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML. *Blood* 2009;114:2220–2231.
- Koreth J, Schlenk R, Kopecky KJ, et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. *JAMA* 2009;301:2349–2361.
- Schlenk RF, Taskesen E, van Norden Y, et al. The value of allogeneic and autologous hematopoietic stem cell transplantation in prognostically favorable acute myeloid leukemia with double mutant CEBPA. *Blood* 2013;122:1576–1582.
- Geyer S, Zhao J, Carroll AJ, et al. Adding the KIT inhibitor dasatinib (DAS) to standard induction and consolidation therapy for newly diagnosed patients (pts) with core binding factor (CBF) acute myeloid leukemia (AML): initial results of the CALGB 10801 (Alliance) study. *Blood* 2013;122:357.
- Petersdorf S, Estey EH, Othus M, et al. The addition of gemtuzumab ozogamicin (GO) to induction chemotherapy reduces relapse and improves survival in patients without adverse risk karyotype: results of an individual patient meta-analysis of the five randomised trials. *Blood* 2013;122:356.
- Ravandi F, Estey EH, Appelbaum FR, et al. Gemtuzumab ozogamicin: time to resurrector? *J Clin Oncol* 2012;30:3921–3923.
- Woods W, Kobrinsky N, Buckley J, et al. Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: a report from the Children's Cancer Group. *Blood* 1996;87:4979–4989.
- Burnett AK, Russell NH, Kell J, et al. A comparison of daunorubicin/Ara-C (DA) versus daunorubicin/clofarabine (DClo) and two versus three courses of total treatment for older patients with AML and high risk MDS: results of the UK NCRI AML16 trial. *ASH Annual Meeting Abstracts* 2012;120:892.
- Burnett AK, Russell NH, Hunter AE, et al. Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival. *Blood* 2013;122:1384–94.
- Faderl S, Wetzler M, Rizzieri D, et al. Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial. *J Clin Oncol* 2012;30:2492–2499.

51. Quintas-Cardama A, Ravandi F, Liu-Dumlao T, et al. Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia. *Blood* 2012;120:4840–4845.
52. Kantarjian HM, Thomas XG, Dmoszynska A, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. *J Clin Oncol* 2012;30:2670–2677.
53. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. *J Clin Oncol* 2010;28:562–569.
54. Boumber Y, Kantarjian H, Jorgensen J, et al. A randomized study of decitabine versus conventional care for maintenance therapy in patients with acute myeloid leukemia in complete remission. *Leukemia* 2012;26:2428–2431.
55. de Lima M, Giralt S, Thall PF, et al. Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study. *Cancer* 2010;116:5420–5431.
56. Jabbour E, Yee K, Kropf P, et al. First clinical results of a randomized phase 2 study of SGI-110, a novel subcutaneous (SQ) hypomethylating agent (HMA), in adult patients with acute myeloid leukemia (AML). *Blood* 2013;122:497.
57. Estey EH. Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia. *Leukemia* 2013;27:1803–1812.
58. Estey EH, Shen Y, Thall PF. Effect of time to complete remission on subsequent survival and disease-free survival time in AML, RAEB-t, and RAEB. *Blood* 2000;95:72–77.
59. Cilloni D, Renneville A, Hermitte F, et al. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study. *J Clin Oncol* 2009;27:5195–5201.
60. Burnett AK, Goldstone A, Hills RK, et al. Curability of patients with acute myeloid leukemia who did not undergo transplantation in first remission. *J Clin Oncol* 2013;31(10):1293–301.
61. Gale RE, Green C, Allen C, et al. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. *Blood* 2008;111:2776–2784.
62. Cortes JE, Kantarjian H, Foran JM, et al. Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status. *J Clin Oncol* 2013;31:3681–3687.
63. Foran JM, Pratz KW, Trone D, et al. Results of a phase 1 study of quizartinib (AC220, ASP2689) in combination with induction and consolidation chemotherapy in younger patients with newly diagnosed acute myeloid leukemia. *Blood* 2013;122:623.
64. Serve H, Krug U, Wagner R, et al. Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial. *J Clin Oncol* 2013;31:3110–3118.
65. Rollig C, Muller-Tidow C, Huttmann A, et al. Sorafenib versus placebo in addition to standard therapy in adult patients ≥ 60 years with newly diagnosed acute myeloid leukemia: results from the randomized-controlled soraml trial. *ASH Annual Meeting Abstracts* 2012;120:144.
66. Galanis A, Ma H, Rajkhowa T, et al. Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants. *Blood* 2014;123:94–100.
67. O'Donnell MR, Tallman MS, Abboud CN, et al. Acute myeloid leukemia, version 2.2013. *J Natl Compr Canc Netw* 2013;11:1047–1055.
68. Sekeres MA, Stone RM, Zahrieh D, et al. Decision-making and quality of life in older adults with acute myeloid leukemia or advanced myelodysplastic syndrome. *Leukemia* 2004;18:809–816.
69. Sanz MA, Grimwade D, Tallman MS, et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. *Blood* 2009;113:1875–1891.
70. Estey E, Thall P, Kantarjian H, et al. Association between increased body mass index and a diagnosis of acute promyelocytic leukemia in patients with acute myeloid leukemia. *Leukemia* 1997;11:1661–1664.
71. Paietta E, Andersen J, Racevskis J, et al. Significantly lower P-glycoprotein expression in acute promyelocytic leukemia than in other types of acute myeloid leukemia: immunological, molecular and functional analyses. *Leukemia* 1994;8:968–973.
72. Lo-Coco F, Cimino G, Breccia M, et al. Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia. *Blood* 2004;104:1995–1999.
73. Ades L, Chevret S, Raffoux E, et al. Long-term follow-up of European APL 2000 trial, evaluating the role of cytarabine combined with ATRA and Daunorubicin in the treatment of nonelderly APL patients. *Am J Hematol* 2013;88:556–559.
74. Powell BL, Moser B, Stock W, et al. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. *Blood* 2010;116:3751–3757.
75. Estey E, Garcia-Manero G, Ferrajoli A, et al. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. *Blood* 2006;107:3469–3473.
76. Lo-Coco F, Awisati G, Vignetti M, et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. *N Engl J Med* 2013;369:1111–1121.
77. Iland HJ, Bradstock K, Supple SC, et al. All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4). *Blood* 2012;120:1570–1580.
78. Park JH, Qiao B, Panageas KS, et al. Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid. *Blood* 2011;118:1248–1254.
79. Breems DA, Van Putten WL, Huijgens PC, et al. Prognostic index for adult patients with acute myeloid leukemia in first relapse. *J Clin Oncol* 2005;23:1969–1978.
80. Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. *Blood* 1990;75:555–562.
81. Schlenk RF, Döhner K, Krauter J, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. *N Engl J Med* 2008;358:1909–1918.
82. Litzow MR, Tarima S, Pérez WS, et al. Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia. *Blood* 2010;115:1850–1857.
83. Walter RB, Cooley TA, Wood BL, et al. Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia. *J Clin Oncol* 2011;29:1190–1197.
84. Ustun C, Wiseman AC, Defor TE, et al. Achieving stringent CR is essential before reduced-intensity conditioning allogeneic hematopoietic cell transplantation in AML. *Bone Marrow Transplant* 2013;48:1415–1420.
85. Walter RB, Buckley SA, Pagel JM, et al. Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission. *Blood* 2013;122:1813–1821.
86. Duval M, Klein JP, He W, et al. Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. *J Clin Oncol* 2010;28:3730–3738.
87. Thomas ED, Buckner CD, Banaji M, et al. One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. *Blood* 1977;49:511–533.
88. Santos GW, Tutschka PJ, Brookmeyer R, et al. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. *N Engl J Med* 1983;309:1347–1353.
89. Andersson BS, de Lima M, Thall PF, et al. Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS. *Biol Blood Marrow Transplant* 2008;14:672–684.
90. Ringden O, Remberger M, Ruutu T, et al. Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis, and alopecia with busulfan versus total body irradiation: long-term results of a randomized trial in allogeneic marrow recipients with leukemia. *Blood* 1999;93:2196–2201.
91. Blaise D, Maraninchi D, Michallet M, et al. Long-term follow-up of a randomized trial comparing the combination of cyclophosphamide with total body irradiation or busulfan as conditioning regimen for patients receiving HLA-identical marrow grafts for acute myeloblastic leukemia in first complete remission. *Blood* 2001;97:3669–3671.
92. Copelan EA, Hamilton BK, Avalos B, et al. Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI. *Blood* 2013;122:3863–3870.
93. Bredeson C, Lerademacher J, Kato K, et al. Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation. *Blood* 2013;122:3871–3878.
94. Nagler A, Rocha V, Labopin M, et al. Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus Cy as conditioning regimen—a report from the acute leukemia working party of the European group for blood and marrow transplantation. *J Clin Oncol* 2013;31:3549–3556.
95. de Lima M, Anagnostopoulos A, Munsell M, et al. Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. *Blood* 2004;104:865–872.
96. Baron F, Maris MB, Sandmaier BM, et al. Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. *J Clin Oncol* 2005;23:1993–2003.
97. Childs R, Clave E, Contentin N, et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. *Blood* 1999;94:3234–3241.
98. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. *Blood* 1998;91:756–763.
99. Giralt S, Thall PF, Khouri I, et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. *Blood* 2001;97:631–637.
100. Kottaridis PD, Milligan DW, Chopra R, et al. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. *Blood* 2000;96:2419–2425.

101. Bayraktar UD, de Lima M, Saliba RM, et al. Ex vivo T cell-depleted versus unmodified allografts in patients with acute myeloid leukemia in first complete remission. *Biol Blood Marrow Transplant* 2013;19:898–903.
102. Oran B, Giral S, Saliba R, et al. Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan. *Biol Blood Marrow Transplant* 2007;13:454–462.
103. Feinstein LC, Sandmaier BM, Hegenbart U, et al. Non-myeloablative allografting from human leucocyte antigen-identical sibling donors for treatment of acute myeloid leukaemia in first complete remission. *Br J Haematol* 2003;120:281–288.
104. Cassileth PA, Harrington DP, Appelbaum FR, et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. *N Engl J Med* 1998;339:1649–1656.
105. Burnett AK, Wheatley K, Goldstone AH, et al. The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial. *Br J Haematol* 2002;118:385–400.
106. Zittoun RA, Mandelli F, Willemze R, et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. *N Engl J Med* 1995;332:217–223.
107. Suciu S, Mandelli F, de Witte T, et al. Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CRI): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial. *Blood* 2003;102:1232–1240.
108. Warlick ED, Paulson K, Brazauskas R, et al. Effect of postremission therapy before reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia in first complete remission. *Biol Blood Marrow Transplant* 2014;20:202–208.
109. Tallman MS, Pérez WS, Lazarus HM, et al. Pretransplantation consolidation chemotherapy decreases leukemia relapse after autologous blood and bone marrow transplants for acute myelogenous leukemia in first remission. *Biol Blood Marrow Transplant* 2006;12:204–216.
110. Jourdan E, Boiron JM, Dastugue N, et al. Early allogeneic stem-cell transplantation for young adults with acute myeloblastic leukemia in first complete remission: an intent-to-treat long-term analysis of the BGMT experience. *J Clin Oncol* 2005;23:7676–7684.
111. Cornelissen JJ, van Putten WL, Verdonck LF, et al. Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? *Blood* 2007;109:3658–3666.
112. Estey E, de Lima M, Tibes R, et al. Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). *Blood* 2007;109:1395–1400.
113. Sorror ML, Appelbaum FR. Risk assessment before allogeneic hematopoietic cell transplantation for older adults with acute myeloid leukemia. *Expert Rev Hematol* 2013;6:547–562.
114. Mawad R, Gooley TA, Sandhu V, et al. Frequency of allogeneic hematopoietic cell transplantation among patients with high- or intermediate-risk acute myeloid leukemia in first complete remission. *J Clin Oncol* 2013;31:3883–3888.
115. Flomenberg N, Baxter-Lowe IA, Confer D, et al. Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome. *Blood* 2004;104:1923–1930.
116. Venstrom JM, Pittari G, Gooley TA, et al. HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1. *N Engl J Med* 2012;367:805–816.
117. Brenner M, Krance R, Heslop HE, et al. Assessment of the efficacy of purging by using gene marked autologous marrow transplantation for children with AML in first complete remission. St. Jude Children's Research Hospital, Memphis, Tennessee. *Human gene therapy* 1994;5:481–499.
118. Champlin R. Purging: the separation of normal from malignant cells for autologous transplantation. *Transfusion* 1996;36:910–918.
119. Miller CB, Rowings PA, Zhang MJ, et al. The effect of graft purging with 4-hydroperoxycyclophosphamide in autologous bone marrow transplantation for acute myelogenous leukemia. *Exp Hematol* 2001;29:1336–1346.
120. Pffrman M, Ehniger G, Thiede C, et al. Prediction of post-remission survival in acute myeloid leukaemia: a post-hoc analysis of the AML96 trial. *Lancet Oncol* 2012;13:207–214.
121. Koreth J, Schlenk R, Kopecky KJ, et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission. *JAMA* 2009;301:2349–2361.
122. Cornelissen JJ, Gratwohl A, Schlenk RF, et al. The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach. *Nat Rev Clin Oncol* 2012;9:579–90.
123. Forman SJ, Schmidt G, Nademanee A, et al. Allogeneic bone marrow transplantation as therapy for primary induction failure for patients with acute leukemia. *J Clin Oncol* 1991;9:1570–1574.
124. Appelbaum FR, Clift R, Buckner CD, et al. Allogeneic marrow transplantation for acute nonlymphoblastic leukemia after first relapse. *Blood* 1983;61:949–953.
125. Armistead PM, de Lima M, Pierce S, et al. Quantifying the survival benefit for allogeneic hematopoietic stem cell transplantation in relapsed acute myelogenous leukemia. *Biol Blood Marrow Transplant* 2009;15:1431–1438.
126. Eapen M, Klein JP, Ruggeri A, et al. Impact of allele-level HLA matching on outcomes after myeloablative single unit umbilical cord blood transplantation for hematologic malignancy. *Blood* 2014;123:133–140.
127. Rocha V, Labopin M, Sanz G, et al. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. *N Engl J Med* 2004;351:2276–2285.
128. Peffault de Latour R, Brunstein CG, Porcher R, et al. Similar overall survival using sibling, unrelated donor, and cord blood grafts after reduced-intensity conditioning for older patients with acute myelogenous leukemia. *Biol Blood Marrow Transplant* 2013;19:1355–1360.
129. Majhail NS, Brunstein CG, Tomblyn M, et al. Reduced-intensity allogeneic transplant in patients older than 55 years: unrelated umbilical cord blood is safe and effective for patients without a matched related donor. *Biol Blood Marrow Transplant* 2008;14:282–289.
130. Eapen M, Klein JP, Sanz GF, et al. Effect of donor-recipient HLA matching at HLA A, B, C, and DRB1 on outcomes after umbilical-cord blood transplantation for leukaemia and myelodysplastic syndrome: a retrospective analysis. *Lancet Oncol* 2011;12:1214–1221.
131. Metheny L, Caimi P, de Lima M. Cord blood transplantation: can we make it better? *Front Oncol* 2013;3:238.
132. de Lima M, McNiece I, Robinson SN, et al. Cord-blood engraftment with ex vivo mesenchymal-cell coculture. *N Engl J Med* 2012;367:2305–2315.
133. Aversa F, Tabilio A, Velardi A, et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. *N Engl J Med* 1998;339:1186–1193.
134. Luznik L, Fuchs EJ. High-dose, post-transplantation cyclophosphamide to promote graft-host tolerance after allogeneic hematopoietic stem cell transplantation. *Immunol Res* 2010;47:65–77.
135. Ruggeri L, Capanni M, Mancusi A, et al. Natural killer cell alloreactivity in haploidentical hematopoietic stem cell transplantation. *Int J Hematol* 2005;81:13–17.
136. Oran B, Giral S, Couriel D, et al. Treatment of AML and MDS relapsing after reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation. *Leukemia* 2007;21:2540–2544.
137. Vago L, Perna SK, Zanussi M, et al. Loss of mismatched HLA in leukemia after stem-cell transplantation. *N Engl J Med* 2009;361:478–488.
138. Cairo MS, Jordan CT, Maley CC, et al. NCI first international workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on the biological considerations of hematological relapse following allogeneic stem cell transplantation unrelated to graft-versus-tumor effects: state of the science. *Biol Blood Marrow Transplant* 2010;16:709–728.
139. Goodyear OC, Dennis M, Jilani NY, et al. Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML). *Blood* 2012;119:3361–3369.
140. Bashir Q, William BM, Garcia-Manero G, et al. Epigenetic therapy in allogeneic hematopoietic stem cell transplantation. *Rev Bras Hematol Hemoter* 2013;35:126–133.
141. Gress RE, Miller JS, Battitwalla M, et al. Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: Part I. Biology of relapse after transplantation. *Biol Blood Marrow Transplant* 2013;19:1537–1545.
142. Hourigan CS, McCarthy P, de Lima M. Back to the future! The evolving role of maintenance therapy after hematopoietic stem cell transplantation. *Biol Blood Marrow Transplant* 2014;20:154–163.
143. de Lima M, Porter DL, Battitwalla M, et al. Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: Part III. Prevention and Treatment of Relapse after Allogeneic Transplantation. *Biol Blood Marrow Transplant* 2014;20:4–13.
144. Hoelzer D, Göckbuget N. Recent approaches in acute lymphoblastic leukemia in adults. *Crit Rev Oncol Hematol* 2000;36:49–58.
145. Coustan-Smith E, Mullighan CG, Onciu M, et al. Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. *Lancet Oncol* 2009;10:147–156.
146. Faderl S, Kantarjian HM, Talpaz M, et al. Clinical significance of cytogenetic abnormalities in adult acute lymphoblastic leukemia. *Blood* 1998;91:3995–4019.
147. Szczepanski T, Harrison CJ, van Dongen JJ. Genetic aberrations in paediatric acute leukaemias and implications for management of patients. *Lancet Oncol* 2010;11:880–889.
148. Moorman AV, Chilton L, Wilkinson J, et al. A population-based cytogenetic study of adults with acute lymphoblastic leukemia. *Blood* 2010;115:206–214.

149. Moorman AV, Harrison CJ, Buck GA, et al. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. *Blood* 2007;109:3189–3197.
150. Moorman AV, Ensor HM, Richards SM, et al. Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97/99 randomised trial. *Lancet Oncol* 2010;11:429–438.
151. Brüggemann M, Raff T, Flohr T, et al. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. *Blood* 2006;107:1116–1123.
152. Patel B, Rai L, Buck G, et al. Minimal residual disease is a significant predictor of treatment failure in non T-lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII/ECOG2993. *Br J Haematol* 2010;148:80–89.
153. Ebert BL, Golub TR. Genomic approaches to hematologic malignancies. *Blood* 2004;104:923–932.
154. Fine BM, Stanulla M, Schrappe M, et al. Gene expression patterns associated with recurrent chromosomal translocations in acute lymphoblastic leukemia. *Blood* 2004;103:1043–1049.
155. Mullighan CG, Goorha S, Radtke I, et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. *Nature* 2007;446:758–764.
156. Vilimas T, Mascarenhas J, Palomero T, et al. Targeting the NF-kappaB signaling pathway in Notch1-induced T-cell leukemia. *Nat Med* 2007;13:70–77.
157. Hagemeijer A, Graux C. ABL1 rearrangements in T-Cell acute lymphoblastic leukemia. *Genes Chromosomes Cancer* 2010;49:299–308.
158. Graux C, Cools J, Melotte C, et al. Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia. *Nat Genet* 2004;36:1084–1089.
159. Grabher C, Harald von Boehmer A. Notch 1 activation in the molecular pathogenesis of T-cell acute lymphoblastic leukaemia. *Nat Rev Cancer* 2006;6:347–359.
160. Mullighan CG, Su X, Zhang J, et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. *N Engl J Med* 2009;360:470–480.
161. Tsutsumi S, Taketani T, Nishimura K, et al. Two distinct gene expression signatures in pediatric acute lymphoblastic leukemia with MLL rearrangements. *Cancer Res* 2003;63:4882–4887.
162. Holleman A, Cheok MH, den Boer ML, et al. Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. *N Engl J Med* 2004;351:533–542.
163. Mullighan CG, Miller CB, Radtke I, et al. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. *Nature* 2008;453:110–114.
164. Roberts KG, Morin RD, Zhang J, et al. Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. *Cancer Cell* 2012;22:153–166.
165. Maude SL, Tasian SK, Vincent T, et al. Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia. *Blood* 2012;120:3510–3518.
166. Koyama D, Kikuchi J, Hiraoka N, et al. Proteasome inhibitors exert cytotoxicity and increase chemosensitivity via transcriptional repression of Notch1 in T-cell acute lymphoblastic leukemia. *Leukemia* 2014;28:1216–1226.
167. Yang JJ, Cheng C, Yang W, et al. Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia. *JAMA* 2009;301:393–403.
168. Evans WE, Relling MV. Moving towards individualized medicine with pharmacogenomics. *Nature* 2004;429:464–468.
169. Relling MV, Ramsey LB. Pharmacogenomics of acute lymphoid leukemia: new insights into treatment toxicity and efficacy. *Hematology Am Soc Hematol Educ Program* 2013;2013:126–130.
170. Belkov VM, Krynetski EY, Schuetz JD, et al. Reduced folate carrier expression in acute lymphoblastic leukemia: a mechanism for ploidy but not lineage differences in methotrexate accumulation. *Blood* 1999;93:1643–1650.
171. Rocha JC, Cheng C, Liu W, et al. Pharmacogenetics of outcome in children with acute lymphoblastic leukemia. *Blood* 2005;105:4752–4758.
172. Garcia-Manero G, Yang H, Kuang SQ, et al. Epigenetics of acute lymphocytic leukemia. *Semin Hematol* 2009;46:24–32.
173. Roman-Gomez J, Agirre X, Jimenez-Velasco A, et al. Epigenetic regulation of microRNAs in acute lymphoblastic leukemia. *J Clin Oncol* 2009;27:1316–1322.
174. Geng H, Brennan S, Milne TA, et al. Integrative epigenomic analysis identifies biomarkers and therapeutic targets in adult B-acute lymphoblastic leukemia. *Cancer Discov* 2012;2:1004–1023.
175. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. *N Engl J Med* 2006;354:166–178.
176. Rowe JM. Prognostic factors in adult acute lymphoblastic leukaemia. *Br J Haematol* 2010;150:389–405.
177. Gökbuget N, Hoelzer D. Treatment of adult acute lymphoblastic leukemia. *ASH Education Program Book* 2006;2006:133–141.
178. Pui CH, Evans WE. Acute lymphoblastic leukemia. *N Engl J Med* 1998;339:605–615.
179. Czuczman MS, Dodge RK, Stewart CC, et al. Value of immunophenotype in intensively treated adult acute lymphoblastic leukemia: cancer and leukemia Group B study 8364. *Blood* 1999;93:3931–3939.
180. Thomas DA, O'Brien S, Kantarjian HM. Monoclonal antibody therapy with rituximab for acute lymphoblastic leukemia. *Hematol Oncol Clin North Am* 2009;23:949–971.
181. Yanada M, Takeuchi J, Sugiura I, et al. High complete remission rate and promising outcome by combination of Imatinib and chemotherapy for newly diagnosed BCR-ABL-Positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. *J Clin Oncol* 2006;24:460–466.
182. Thomas DA, Faderl S, Cortes J, et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. *Blood* 2004;103:4396–4407.
183. de Labarthe A, Rousselot P, Huguet-Rigal F, et al. Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. *Blood* 2007;109:1408–1413.
184. Rowe JM, Buck G, Burnett AK, et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. *Blood* 2005;106:3760–3767.
185. Gökbuget N, Baur K-H, Beck J, et al. Dexamethasone Dose and Schedule Significantly Influences Remission Rate and Toxicity of Induction Therapy in Adult Acute Lymphoblastic Leukemia (ALL): Results of the GMALL Pilot Trial 06/99. *Blood* 2005;106:1832–1832.
186. Annino L, Vegna ML, Camera A, et al. Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study. *Blood* 2002;99:863–871.
187. Kantarjian HM, O'Brien S, Smith TL, et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. *J Clin Oncol* 2000;18:547–561.
188. Hallbook H, Simonsson B, Ahlgren T, et al. High-dose cytarabine in upfront therapy for adult patients with acute lymphoblastic leukaemia. *Br J Haematol* 2002;118:748–754.
189. DeAngelo DJ. The treatment of adolescents and young adults with acute lymphoblastic leukemia. *ASH Education Program Book* 2005;2005:123–130.
190. Larson RA, Dodge RK, Linker CA, et al. A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111. *Blood* 1998;92:1556–1564.
191. Ribera JM, Ortega JJ, Oriol A, et al. Late intensification chemotherapy has not improved the results of intensive chemotherapy in adult acute lymphoblastic leukemia. Results of a prospective multicenter randomized trial (PETHEMA ALL-89). Spanish Society of Hematology. *Haematologica* 1998;83:222–230.
192. Durrant I, Grant Prentice H, Richards S. Intensification of treatment for adults with acute lymphoblastic leukaemia: results of UK Medical Research Council randomized trial UKALL XA. *Br J Haematol* 1997;99:84–92.
193. Larson RA, Dodge R, Burns C, et al. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. *Blood* 1995;85:2025–2037.
194. Kantarjian HM, Walters RS, Keating MJ, et al. Experience with vincristine, doxorubicin, and dexamethasone (VAD) chemotherapy in adults with refractory acute lymphocytic leukemia. *Cancer* 1989;64:16–22.
195. Gökbuget N, Arnold R, Buechner T, et al. Intensification of induction and consolidation improves only subgroups of adult ALL: Analysis of 1200 patients in GMALL study 05/93. *Blood* 2001;98:802a.
196. Chao NJ, Forman SJ, Schmidt GM, et al. Allogeneic bone marrow transplantation for high-risk acute lymphoblastic leukemia during first complete remission. *Blood* 1991;78:1923–1927.
197. Thiebaut A, Vernant JP, Degos L, et al. Adult acute lymphocytic leukemia study testing chemotherapy and autologous and allogeneic transplantation: a follow-up report of the French protocol LALA 87. *Hematol Oncol Clin North Am* 2000;14:1353–1366.
198. Thomas X, Boiron JM, Huguet F, et al. Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. *J Clin Oncol* 2004;22:4075–4086.
199. Goldstone AH, Richards SM, Lazarus HM, et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). *Blood* 2008;111:1827–1833.
200. Cornelissen JJ, van der Holt B, Verhoef GE, et al. Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: a prospective sibling donor versus non-donor comparison. *Blood* 2009;113:1375–1382.
201. Takeuchi J, Kyo T, Naito K, et al. Induction therapy by frequent administration of doxorubicin with four other drugs, followed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia: the JALSG-ALL93 study. *Leukemia* 2002;16:1259–1266.
202. Labar B, Suci S, Zittoun R, et al. Allogeneic stem cell transplantation in acute lymphoblastic leukemia and non-Hodgkin's lymphoma for patients < or = 50 years old in first complete remission: results of the EORTC ALL-3 trial. *Haematologica* 2004;89:809–817.

203. Ribera JM, Oriol A, Bethencourt C, et al. Comparison of intensive chemotherapy, allogeneic or autologous stem cell transplantation as post-remission treatment for adult patients with high-risk acute lymphoblastic leukemia. Results of the PETHEMA ALL-93 trial. *Haematologica* 2005;90:1346–1356.
204. Marks DI, Forman SJ, Blume KG, et al. A comparison of cyclophosphamide and total body irradiation with etoposide and total body irradiation as conditioning regimens for patients undergoing sibling allografting for acute lymphoblastic leukemia in first or second complete remission. *Biol Blood Marrow Transplant* 2006;12:438–453.
205. Blume KG, Kopecky KJ, Henslee-Downey JP, et al. A prospective randomized comparison of total body irradiation-etoposide versus busulfan-cyclophosphamide as preparatory regimens for bone marrow transplantation in patients with leukemia who were not in first remission: a Southwest Oncology Group study. *Blood* 1993;81:2187–2193.
206. Marks DI, Wang T, Pérez WS, et al. The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome–negative acute lymphoblastic leukemia in first and second complete remission. *Blood* 2010;116:366–374.
207. Mohy M, Labopin M, Tabrizi R, et al. Reduced intensity conditioning allogeneic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation. *Haematologica* 2008;93:303–306.
208. Stein AS, Palmer JM, O'Donnell MR, et al. Reduced-intensity conditioning followed by peripheral blood stem cell transplantation for adult patients with high-risk acute lymphoblastic leukemia. *Biol Blood Marrow Transplant* 2009;15:1407–1414.
209. Hamaki T, Kami M, Kanda Y, et al. Reduced-intensity stem-cell transplantation for adult acute lymphoblastic leukemia: a retrospective study of 33 patients. *Bone Marrow Transplant* 2005;35:549–556.
210. Martino R, Giral T, Caballero MD, et al. Allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning in acute lymphoblastic leukemia: a feasibility study. *Haematologica* 2003;88:555–560.
211. Aricó M, Baruchel A, Bertrand Y, et al. The seventh international childhood acute lymphoblastic leukemia workshop report: Palermo, Italy, January 29–30, 2005. *Leukemia* 2005;19:1145–1152.
212. Pfeifer H, Wassmann B, Bethge W, et al. Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia. *Leukemia* 2013;27:1254–1262.
213. Cortes J, O'Brien SM, Pierce S, et al. The value of high-dose systemic chemotherapy and intrathecal therapy for central nervous system prophylaxis in different risk groups of adult acute lymphoblastic leukemia. *Blood* 1995;86:2091–2097.
214. Wetzler M, Dodge RK, Mrozek K, et al. Prospective karyotype analysis in adult acute lymphoblastic leukemia: the cancer and leukemia Group B experience. *Blood* 1999;93:3983–3993.
215. Laport GG, Alvarnas JC, Palmer JM, et al. Long-term remission of Philadelphia chromosome–positive acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation from matched sibling donors: a 20-year experience with the fractionated total body irradiation–etoposide regimen. *Blood* 2008;112:903–909.
216. Snyder D, Nademanee A, O'Donnell M, et al. Long-term follow-up of 23 patients with Philadelphia chromosome–positive acute lymphoblastic leukemia treated with allogeneic bone marrow transplant in first complete remission. *Leukemia* 1999;13:2053–2058.
217. Fielding AK, Rowe JM, Richards SM, et al. Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome–positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII/ECOG2993. *Blood* 2009;113:4489–4496.
218. Cornelissen JJ, Carston M, Kollman C, et al. Unrelated marrow transplantation for adult patients with poor-risk acute lymphoblastic leukemia: strong graft-versus-leukemia effect and risk factors determining outcome. *Blood* 2001;97:1572–1577.
219. Ottmann OG, Druker BJ, Sawyers CL, et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome–positive acute lymphoid leukemias. *Blood* 2002;100:1965–1971.
220. Lee S, Kim YJ, Min CK, et al. The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia. *Blood* 2005;105:3449–3457.
221. Tanguy-Schmidt A, Rousselot P, Chalandon Y, et al. Long-term follow-up of the imatinib GRAAPH-2003 study in newly diagnosed patients with de novo Philadelphia chromosome–positive acute lymphoblastic leukemia: a GRAALL study. *Biol Blood Marrow Transplant* 2013;19:150–155.
222. Delannoy A, Delabesse E, Lheritier V, et al. Imatinib and methylprednisolone alternated with chemotherapy improve the outcome of elderly patients with Philadelphia–positive acute lymphoblastic leukemia: results of the GRAALL AFR09 study. *Leukemia* 2006;20:1526–1532.
223. Vignetti M, Fazi P, Cimino G, et al. Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome–positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) LAL0201-B protocol. *Blood* 2007;109:3676–3678.
224. Ottmann OG, Wassmann B, Pfeifer H, et al. Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL). *Cancer* 2007;109:2068–2076.
225. Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome–positive leukemias. *N Engl J Med* 2006;354:2531–2541.
226. Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome–positive ALL. *N Engl J Med* 2006;354:2542–2551.
227. Cortes J, Rousselot P, Kim DW, et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or-intolerant chronic myeloid leukemia in blast crisis. *Blood* 2007;109:3207–3213.
228. Ottmann O, Dombret H, Martinelli G, et al. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. *Blood* 2007;110:2309–2315.
229. Lilly MB, Ottmann OG, Shah NP, et al. Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study. *Am J Hematol* 2010;85:164–170.
230. Ravandi F, O'Brien S, Thomas D, et al. First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia. *Blood* 2010;116:2070–2077.
231. Ravandi F, Jorgensen JL, Thomas DA, et al. Detection of MRD may predict the outcome of patients with Philadelphia chromosome–positive ALL treated with tyrosine kinase inhibitors plus chemotherapy. *Blood* 2013;122:1214–1221.
232. Blum KA, Lozanski G, Byrd JC. Adult Burkitt leukemia and lymphoma. *Blood* 2004;104:3009–3020.
233. Rizzieri DA, Johnson JL, Niedzwiecki D, et al. Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma: final results of Cancer and Leukemia Group B Study 9251. *Cancer* 2004;100:1438–1448.
234. Thomas DA, Faderl S, O'Brien S, et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. *Cancer* 2006;106:1569–1580.
235. Vitale A, Guarini A, Ariola C, et al. Adult T-cell acute lymphoblastic leukemia: biologic profile at presentation and correlation with response to induction treatment in patients enrolled in the GIMEMA LAL 0496 protocol. *Blood* 2006;107:473–479.
236. Marks DI, Paietta EM, Moorman AV, et al. T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993). *Blood* 2009;114:5136–5145.
237. Ravandi F, Gandhi V. Novel purine nucleoside analogues for T-cell-lineage acute lymphoblastic leukaemia and lymphoma. *Expert Opin Investig Drugs* 2006;15:1601–1613.
238. DeAngelo DJ, Yu D, Johnson JL, et al. Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801. *Blood* 2007;109:5136–5142.
239. Gokbuget N, Basara N, Baurmann H, et al. High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation. *Blood* 2011;118:3504–3511.
240. Dunsmore KP, Devidas M, Linda SB, et al. Pilot study of nelarabine in combination with intensive chemotherapy in high-risk T-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group. *J Clin Oncol* 2012;30:2753–2759.
241. Terwey T, Massenkeil G, Tamm I, et al. Allogeneic SCT in refractory or relapsed adult ALL is effective without prior reinduction chemotherapy. *Bone Marrow Transplant* 2008;42:791–798.
242. Biggs JC, Horowitz MM, Gale RP, et al. Bone marrow transplants may cure patients with acute leukemia never achieving remission with chemotherapy. *Blood* 1992;80:1090–1093.
243. Capizzi RL, Poole M, Cooper MR, et al. Treatment of poor risk acute leukemia with sequential high-dose ARA-C and asparaginase. *Blood* 1984;63:694–700.
244. Kantarjian HM, Walters RL, Keating MJ, et al. Mitoxantrone and high-dose cytosine arabinoside for the treatment of refractory acute lymphocytic leukemia. *Cancer* 1990;65:5–8.
245. Fielding AK, Richards SM, Chopra R, et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL): an MRC UKALL12/ECOG 2993 study. *Blood* 2007;109:944–950.
246. Oriol A, Vives S, Hernández-Rivas JM, et al. Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group. *Haematologica* 2010;95:589–596.
247. Kantarjian H, Thomas D, Jorgensen J, et al. Inotuzumab ozogamicin, an anti-CD22–calceamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. *Lancet Oncol* 2012;13:403–411.
248. Topp MS, Kufer P, Gokbuget N, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results

- in high response rate and prolonged leukemia-free survival. *J Clin Oncol* 2011;29:2493–2498.
249. Zhang J, Ding L, Holmfeldt L, et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. *Nature* 2012;481:157–163.
250. Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. *N Engl J Med* 2013;368:1509–1518.
251. Brentjens RJ, Davila ML, Riviere I, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. *Sci Transl Med* 2013;5:177ra38.
252. Kebriaei P, Huls H, Singh H, et al. First clinical trials employing *Sleeping Beauty* gene transfer system and artificial antigen presenting cells to generate and infuse t cells expressing CD19-specific chimeric antigen receptor. *ASH Annual Meeting Abstracts* 2013:166a.
253. Burnett AK, Goldstone AH, Stevens RM, et al. Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. UK Medical Research Council Adult and Children's Leukaemia Working Parties. *Lancet* 1998;351:700–708.